Back to Publications​
Back to News​
Back to The Biomarker Edge​
Publications

Alamar Biosciences launches the NULISAqpcr™ Custom Assay Development Kit to advance the development of novel biomarker assays for clinical research

  • February 24, 2025
Product:
Topic:
Disease Area:
Sample Type:
Back to Publications​
  • February 24, 2025

 Fremont, CA – February 24, 2025 – Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the NULISAqpcr™ Custom Assay Development Kit, a groundbreaking product that empowers researchers to create highly sensitive and precise biomarker assays tailored to their specific research needs, expanding application of the NULISA™ technology to the broader biomarker research community.

The NULISAqpcr Custom Assay Development Kit provides unmatched flexibility, enabling scientists to utilize their own antibodies to develop targeted assays with exceptional sensitivity and reproducibility.  Ideal for fields requiring high sensitivity and broad dynamic range —such as immunology, neurology, and beyond—this customizable kit offers a seamless workflow from antibody conjugation to automated NULISAqpcr with the ARGO™ HT instrument, setting a new standard for homebrew single-plex assay development.

“The Custom Assay Development Kit is a direct response to the growing demand from researchers eager to harness our cutting-edge NULISA technology to develop high-performance biomarker assays for translational and clinical research,” said Yuling Luo, Ph.D., Founder, Chairman, and CEO of Alamar Biosciences. “This launch marks a major milestone in our mission to build a transformative ecosystem to power precision proteomics.”

With the launch of the NULISAqpcr Custom Assay Development Kit, Alamar continues to demonstrate its commitment to driving innovation and supporting the scientific community with cutting-edge solutions. The NULISAqpcr Custom Assay Development Kit is now available to order for shipments in Q2. 

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.

Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.